Pharmacology of Trastuzumab

Introduction/Overview

Trastuzumab represents a landmark achievement in oncology and molecular pharmacology, being among the first monoclonal antibodies successfully developed to target a specific oncogenic driver. Its introduction fundamentally altered the therapeutic landscape and prognosis for a historically aggressive subtype of cancer. The agent specifically targets the Human Epidermal Growth Factor Receptor 2 (HER2), a transmembrane tyrosine kinase receptor encoded by the ERBB2 gene. HER2 overexpression or gene amplification occurs in approximately 15-20% of breast cancers and in subsets of other malignancies, conferring a more aggressive tumor phenotype and poorer clinical outcomes prior to the advent of targeted therapy. The clinical relevance of trastuzumab is profound, having transformed HER2-positive breast cancer from a diagnosis with a poor prognosis to a manageable chronic condition for many patients, establishing a paradigm for the development of other molecularly targeted agents.

Learning Objectives

Upon completion of this chapter, the reader should be able to:

• Describe the molecular structure of trastuzumab and its classification within the broader context of biologic therapies.
• Explain in detail the multiple proposed mechanisms of action by which trastuzumab exerts its antitumor effects against HER2-positive cells.
• Analyze the unique pharmacokinetic profile of trastuzumab, including its long elimination half-life and the implications for dosing regimens.
• Identify the approved clinical indications for trastuzumab, including specific disease stages and combination regimens.
• Evaluate the major adverse effect profile, with particular emphasis on cardiotoxicity, and outline appropriate monitoring and management strategies.
• Discuss special considerations for the use of trastuzumab in populations such as pregnant patients, the elderly, and those with organ impairment.

Classification

Trastuzumab is classified primarily as a monoclonal antibody (mAb). More specifically, it is a recombinant humanized immunoglobulin G1 (IgG1) kappa monoclonal antibody. The humanization process involved grafting the complementarity-determining regions (CDRs) from a murine monoclonal antibody (4D5) that binds HER2 onto a human IgG1 framework. This engineering results in a molecule that is approximately 95% human in sequence, which significantly reduces immunogenicity compared to a purely murine antibody while retaining high affinity for its target.

From a therapeutic standpoint, trastuzumab falls into several overlapping categories:

• Antineoplastic Agent: A drug used in the treatment of cancer.
• Biologic Therapy/Biopharmaceutical: A therapeutic agent produced through biological processes within living systems, such as mammalian cell culture.
• Targeted Therapy: An agent designed to interfere with specific molecular targets that drive cancer growth and progression.
• Receptor Antagonist/Inhibitor: It functions by binding to and inhibiting the signaling of the HER2 receptor.

Chemically, as a protein, it is not described by a traditional small-molecule chemical structure but by its amino acid sequence. Its molecular weight is approximately 145,531 Daltons.

Mechanism of Action

The antitumor efficacy of trastuzumab is attributed to a multifaceted mechanism of action resulting from its specific binding to the extracellular domain (Subdomain IV) of the HER2 protein. HER2 is a member of the ErbB family of receptor tyrosine kinases, which also includes EGFR (HER1), HER3, and HER4. Unlike other family members, HER2 has no known direct ligand and exists in a constitutively active conformation, primed for dimerization. Overexpression leads to spontaneous homodimerization or heterodimerization with other ErbB members, resulting in autophosphorylation of intracellular tyrosine kinase domains and activation of downstream pro-survival and proliferative signaling pathways, primarily the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt cascades.

Detailed Pharmacodynamics

Trastuzumab’s binding to HER2 initiates several concurrent and sequential pharmacodynamic effects:

1. Inhibition of HER2 Signaling: Binding sterically hinders the cleavage of the extracellular domain, a process known as shedding, which can produce a constitutively active membrane-bound fragment. More importantly, it may induce conformational changes that prevent receptor dimerization, thereby inhibiting downstream signal transduction. This leads to cell cycle arrest in the G1 phase, mediated through induction of the cyclin-dependent kinase inhibitor p27^KIP1 and reduced cyclin D1 expression.
2. Antibody-Dependent Cellular Cytotoxicity (ADCC): This is considered a primary mechanism of action. As an IgG1 antibody, trastuzumab’s Fc region can engage Fcγ receptors (FcγRIIIa, CD16a) on immune effector cells, primarily natural killer (NK) cells, macrophages, and monocytes. This engagement recruits these immune cells to the tumor site, leading to the lysis and phagocytosis of the antibody-coated HER2-positive tumor cells.
3. Inhibition of DNA Repair: Evidence suggests trastuzumab interferes with DNA damage repair mechanisms. It may downregulate proteins involved in non-homologous end joining (NHEJ) and homologous recombination, potentially sensitizing cells to the effects of concurrent DNA-damaging chemotherapy.
4. Inhibition of Angiogenesis: Trastuzumab has been shown to reduce the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and angiopoietin-1, thereby inhibiting the formation of new tumor vasculature.
5. Receptor Internalization and Degradation: Upon antibody binding, the HER2-trastuzumab complex can undergo endocytosis and subsequent lysosomal degradation, leading to a reduction in surface receptor density.

The relative contribution of each mechanism to clinical efficacy remains an area of investigation, but ADCC is widely regarded as critically important. Polymorphisms in the FcγRIIIa receptor, which affect binding affinity, have been correlated with differential clinical responses to trastuzumab in some studies.

Pharmacokinetics

The pharmacokinetics of trastuzumab are characteristic of a monoclonal antibody and differ significantly from those of small-molecule chemotherapeutic agents. Its disposition is governed by specific, saturable binding to the HER2 target and non-specific, linear proteolytic clearance pathways.

Absorption

Trastuzumab is not administered orally due to extensive proteolytic degradation in the gastrointestinal tract and poor absorption. It is administered via intravenous (IV) infusion, providing complete systemic bioavailability. Subcutaneous formulations have also been developed and approved, offering comparable efficacy with a more convenient administration. Following subcutaneous injection, bioavailability is estimated to be approximately 77-80%, with peak concentrations achieved in 2-5 days.

Distribution

The volume of distribution at steady state is relatively small, approximately 2.9 to 4.5 L, which is close to the plasma volume. This indicates limited distribution into tissues, consistent with its large molecular size and hydrophilicity. Distribution is primarily within the vascular and interstitial spaces of well-perfused organs. The agent must distribute to the tumor site to exert its effect, and penetration into solid tumors can be variable, influenced by factors such as tumor vascularity and interstitial pressure.

Metabolism

Like other IgG antibodies, trastuzumab is not metabolized by hepatic cytochrome P450 enzymes. Its catabolism occurs primarily through proteolytic degradation throughout the reticuloendothelial system, following either binding to the HER2 target or via non-specific pinocytosis and lysosomal degradation. The clearance pathway is biphasic. At low concentrations, clearance is dominated by a specific, saturable pathway related to HER2 binding (target-mediated drug disposition). At higher concentrations, this pathway becomes saturated, and a non-specific, linear clearance pathway predominates.

Excretion

Intact trastuzumab is not excreted renally or fecally to a significant degree. The products of its catabolic breakdown (amino acids and small peptides) are recycled in the body’s amino acid pool or excreted via renal mechanisms.

Half-life and Dosing Considerations

The elimination half-life is dose-dependent due to saturable clearance but averages approximately 28 days (range 18-38 days) with weekly dosing and extends to around 30 days with the every-3-week regimen. This prolonged half-life is a key feature influencing dosing schedules. The standard initial (loading) dose for metastatic disease is 4 mg/kg IV, followed by a maintenance dose of 2 mg/kg IV weekly. An alternative regimen uses an 8 mg/kg loading dose followed by 6 mg/kg every three weeks, which is pharmacokinetically equivalent and often preferred for convenience. Steady-state concentrations are typically achieved after 16-20 weeks of weekly dosing. Dosing is based on body weight, and adjustments are generally not required for age, renal impairment, or mild to moderate hepatic impairment. Serum concentrations have shown some correlation with clinical response, with higher trough levels associated with improved outcomes in some analyses.

Therapeutic Uses/Clinical Applications

Trastuzumab is indicated for the treatment of HER2-overexpressing cancers. Determination of HER2 status via immunohistochemistry (IHC) and/or in situ hybridization (ISH) is an absolute prerequisite for therapy initiation.

Approved Indications

• Early-Stage HER2-Positive Breast Cancer:
  • Adjuvant Therapy: Following primary treatment (surgery ± radiotherapy) for node-positive or high-risk node-negative disease. It is administered concurrently with or sequentially to chemotherapy regimens, typically containing anthracyclines and/or taxanes, for a total duration of one year. This use has significantly reduced recurrence rates and improved overall survival.
  • Neoadjuvant Therapy: Administered prior to surgery in combination with chemotherapy for locally advanced or inflammatory breast cancer. This approach can downstage tumors, increase rates of breast-conserving surgery, and provide early prognostic information based on pathological complete response.
• Metastatic HER2-Positive Breast Cancer:
  • Used in combination with first-line chemotherapy, commonly paclitaxel or docetaxel. It can also be combined with other agents like vinorelbine or capecitabine.
  • As monotherapy for patients who have received one or more chemotherapy regimens for metastatic disease.
  • In combination with pertuzumab and docetaxel as first-line treatment for metastatic disease, based on superior outcomes.
  • In combination with hyaluronidase-zzxf (a subcutaneous formulation) for appropriate patients.
• Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma: It is approved for use in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil) for first-line treatment of patients with HER2-overexpressing metastatic adenocarcinoma of the stomach or gastroesophageal junction.

Off-Label Uses

While not formally approved, trastuzumab has been investigated and sometimes used in other HER2-positive malignancies, often in combination with chemotherapy. These include cancers of the colorectum, biliary tract, bladder, and non-small cell lung cancer where HER2 alterations are present. Its use in these settings is generally within clinical trials or as a later-line option based on molecular profiling. In ovarian cancer, its benefit has been limited despite some HER2 expression.

Adverse Effects

The adverse effect profile of trastuzumab is distinct from traditional cytotoxic chemotherapy, with a notable absence of severe myelosuppression, alopecia, or significant nausea and vomiting. However, it carries its own spectrum of toxicities.

Common Side Effects

• Infusion-Related Reactions: Occur during or within 24 hours of the first infusion in up to 40% of patients. Symptoms are typically mild to moderate and may include fever, chills, rigors, nausea, vomiting, pain (at tumor sites, abdominal, back, or chest), headache, dizziness, dyspnea, rash, and hypotension. These reactions are managed by slowing or interrupting the infusion and administering supportive medications like acetaminophen, diphenhydramine, and corticosteroids. Premedication is standard for the initial dose. Reactions are less frequent with subsequent infusions.
• Musculoskeletal Pain: A frequent complaint, often manifesting as arthralgia, myalgia, or bone pain.
• Fatigue: A common, non-specific side effect reported by a majority of patients.
• Gastrointestinal Effects: Diarrhea, nausea, and vomiting are reported, though they are often attributable to concurrent chemotherapy.
• Upper Respiratory Tract Infections: Mild infections such as nasopharyngitis may occur.

Serious/Rare Adverse Reactions

• Cardiotoxicity: This is the most significant and concerning adverse effect. Trastuzumab can induce a decline in left ventricular ejection fraction (LVEF), which may lead to symptomatic congestive heart failure (CHF). The mechanism is not fully elucidated but is distinct from anthracycline-induced cardiotoxicity. It is not dose-dependent and is believed to involve inhibition of HER2 signaling in cardiomyocytes, which is essential for normal cell survival and stress response. The risk is significantly increased when trastuzumab is administered concurrently with or following anthracycline chemotherapy. Symptoms include dyspnea, orthopnea, increased cough, peripheral edema, and S3 gallop. The incidence of symptomatic CHF is approximately 2-4% in adjuvant monotherapy trials but can be higher (up to 16-20%) when combined with anthracyclines.
• Pulmonary Toxicity: Rare but serious events include interstitial pneumonitis, acute respiratory distress syndrome (ARDS), pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, and pulmonary fibrosis. These can be fatal and require immediate intervention.
• Exacerbation of Chemotherapy-Induced Neutropenia: When combined with myelosuppressive chemotherapy, trastuzumab may increase the incidence and severity of neutropenia and febrile neutropenia.
• Hypersensitivity Reactions/Anaphylaxis: Severe hypersensitivity reactions, including anaphylaxis, are possible but uncommon.
• Embryo-Fetal Toxicity: Based on its mechanism and animal data, trastuzumab can cause oligohydramnios, fetal pulmonary hypoplasia, skeletal abnormalities, and fetal death.

Black Box Warnings

The prescribing information for trastuzumab contains boxed warnings for the following:

1. Cardiomyopathy: Trastuzumab can result in subclinical and clinical cardiac failure manifesting as CHF and decreased LVEF. The risk is highest with concurrent anthracycline use. Regular monitoring of cardiac function (e.g., echocardiogram or MUGA scan) is mandatory before and during treatment.
2. Infusion Reactions and Pulmonary Toxicity: Severe and fatal infusion reactions and pulmonary events have been reported.
3. Embryo-Fetal Toxicity: Exposure during pregnancy can result in oligohydramnios and fetal harm. Pregnancy status must be verified prior to initiation, and effective contraception is required during and for several months after treatment.

Drug Interactions

Formal pharmacokinetic drug-drug interaction studies are limited due to its non-CYP metabolic pathway. However, clinically significant interactions exist, primarily related to additive toxicities.

Major Drug-Drug Interactions

• Anthracyclines (e.g., doxorubicin, epirubicin): This combination produces a synergistic risk of cardiotoxicity. Concurrent administration is contraindicated. In adjuvant settings, a non-concurrent approach is used, typically with a taxane-based regimen separating the anthracycline and trastuzumab components, or by using non-anthracycline regimens.
• Other Cardiotoxic Agents: Concomitant use with other drugs known to impair left ventricular function (e.g., certain calcium channel blockers, other tyrosine kinase inhibitors) may potentially increase cardiac risk, necessitating enhanced monitoring.
• Myelosuppressive Chemotherapy: As noted, trastuzumab may exacerbate neutropenia when combined with agents like paclitaxel, docetaxel, or capecitabine.

No clinically significant interactions altering trastuzumab’s clearance have been identified with common supportive care medications.

Contraindications

• Known hypersensitivity to trastuzumab, Chinese hamster ovary cell proteins, or any component of the formulation.
• Concurrent administration with anthracycline chemotherapy for the treatment of breast cancer due to the unacceptable risk of cardiotoxicity. Sequential administration may be permissible with careful monitoring.

Special Considerations

Use in Pregnancy and Lactation

Pregnancy: Trastuzumab is classified as FDA Pregnancy Category D (positive evidence of human fetal risk). HER2 is involved in fetal cardiac and neural development. Exposure during pregnancy, particularly in the second and third trimesters, is associated with oligohydramnios and its sequelae: fetal pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Use during pregnancy is contraindicated unless the potential benefit justifies the potential risk to the fetus, which is an exceedingly rare scenario. Pregnancy testing is required prior to initiation in women of childbearing potential. Effective contraception is recommended during treatment and for at least 7 months after the last dose.

Lactation: It is not known whether trastuzumab is excreted in human milk. However, human IgG is excreted in breast milk. Given the potential for serious adverse reactions in nursing infants and the long half-life of the drug, a decision must be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric and Geriatric Considerations

Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Limited data from small studies suggest potential activity in certain pediatric cancers with HER2 amplification, but its use remains investigational in this population.

Geriatric Use: Clinical studies have included a substantial number of patients aged 65 and over. While no overall differences in safety or efficacy were observed compared to younger patients, greater sensitivity in some older individuals cannot be ruled out. Particular attention should be paid to cardiac monitoring, as age is an independent risk factor for cardiovascular disease. Dose selection should be cautious, starting at the lower end of the dosing range, but standard weight-based dosing is generally applied.

Renal and Hepatic Impairment

Renal Impairment: Formal pharmacokinetic studies in patients with renal impairment have not been conducted. However, because renal clearance is not a major elimination pathway for monoclonal antibodies, no dose adjustments are recommended for mild to moderate renal impairment. Use in patients with severe renal impairment has not been studied, and caution is advised.

Hepatic Impairment: Hepatic metabolism is not involved in trastuzumab clearance. Pharmacokinetic studies have not shown significant differences in patients with mild to moderate hepatic impairment (due to liver metastases). No dose adjustment is recommended for hepatic impairment. Its use in patients with severe hepatic impairment has not been formally studied.

Summary/Key Points

• Trastuzumab is a humanized monoclonal IgG1 antibody targeting the HER2 receptor, a driver oncogene in 15-20% of breast cancers and other malignancies.
• Its mechanism of action is multifactorial, involving inhibition of HER2 signaling, induction of antibody-dependent cellular cytotoxicity (ADCC), inhibition of angiogenesis and DNA repair, and receptor internalization.
• Pharmacokinetics are characterized by slow, non-linear clearance, a long elimination half-life (~28 days), and distribution primarily within the vascular compartment, leading to weight-based dosing on weekly or 3-weekly schedules.
• It is a cornerstone therapy for HER2-positive breast cancer in the adjuvant, neoadjuvant, and metastatic settings, and for HER2-positive metastatic gastric/gastroesophageal junction cancer.
• The most significant adverse effect is cardiotoxicity (reduced LVEF, CHF), warranting mandatory baseline and periodic cardiac monitoring. Severe infusion reactions and pulmonary toxicity are also serious risks.
• Concurrent use with anthracycline chemotherapy is contraindicated due to synergistic cardiotoxicity.
• It is contraindicated in pregnancy due to risks of oligohydramnios and fetal harm. No dose adjustments are recommended for renal or hepatic impairment.

Clinical Pearls

• Accurate HER2 testing (IHC and/or ISH) is mandatory before considering therapy; treatment without confirmation is inappropriate.
• Cardiac monitoring with echocardiogram or MUGA scan is required at baseline, every 3 months during treatment, and at completion. A significant absolute drop in LVEF (typically ≥10-15 percentage points to a value below the lower limit of normal) usually mandates treatment interruption and cardiology consultation.
• For early-stage breast cancer, completing the full 12-month adjuvant course is associated with optimal outcomes; shorter durations have proven inferior in clinical trials.
• Infusion-related reactions are most common with the first dose. Premedication and a slow initial infusion rate are standard. Subcutaneous formulations can mitigate this issue and improve convenience.
• In metastatic disease, treatment is generally continued until disease progression or unacceptable toxicity, reflecting its cytostatic rather than cytotoxic nature.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.